First Time Loading...

Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 33.5 GBX -4.29%
Updated: Mar 29, 2024

Intrinsic Value

RENX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Renalytix Plc manufactures medical devices and equipment. [ Read More ]

The intrinsic value of one RENX stock under the Base Case scenario is 40.61 GBX. Compared to the current market price of 33.5 GBX, Renalytix PLC is Undervalued by 18%.

Key Points:
RENX Intrinsic Value
Base Case
40.61 GBX
Undervaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Renalytix PLC

Backtest RENX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RENX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Renalytix PLC's business.

What risks and challenges
does Renalytix PLC face in the near future?

Summarize the latest earnings report
of Renalytix PLC.

Provide P/E
for Renalytix PLC and its competitors.

Financials

Balance Sheet Decomposition
Renalytix PLC

Current Assets 28.3m
Cash & Short-Term Investments 26.3m
Receivables 776k
Other Current Assets 1.3m
Non-Current Assets 13.8m
PP&E 1.2m
Intangibles 12.5m
Other Non-Current Assets 51k
Current Liabilities 16.1m
Accounts Payable 2.9m
Accrued Liabilities 8.6m
Other Current Liabilities 4.6m
Non-Current Liabilities 7.5m
Long-Term Debt 7.5m
Efficiency

Earnings Waterfall
Renalytix PLC

Revenue
3.4m USD
Cost of Revenue
-2.7m USD
Gross Profit
701k USD
Operating Expenses
-43.1m USD
Operating Income
-42.4m USD
Other Expenses
-3.9m USD
Net Income
-46.2m USD

Free Cash Flow Analysis
Renalytix PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RENX Profitability Score
Profitability Due Diligence

Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Positive 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

RENX Solvency Score
Solvency Due Diligence

Renalytix PLC's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
53/100
Solvency
Score

Renalytix PLC's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RENX Price Targets Summary
Renalytix PLC

Wall Street analysts forecast RENX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RENX is 143.14 GBX with a low forecast of 87.87 GBX and a high forecast of 220.5 GBX.

Lowest
Price Target
87.87 GBX
162% Upside
Average
Price Target
143.14 GBX
327% Upside
Highest
Price Target
220.5 GBX
558% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

RENX Price
Renalytix PLC

1M 1M
-17%
6M 6M
-45%
1Y 1Y
-61%
3Y 3Y
-97%
5Y 5Y
-76%
10Y 10Y
-72%
Annual Price Range
33.5
52w Low
10.25
52w High
145
Price Metrics
Average Annual Return 33.04%
Standard Deviation of Annual Returns 100.26%
Max Drawdown -99%
Shares Statistics
Market Capitalization 31.4m GBX
Shares Outstanding 99 930 100
Percentage of Shares Shorted 205%

RENX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Renalytix PLC Logo
Renalytix PLC

Country

United Kingdom

Industry

Health Care

Market Cap

31.4m GBP

Dividend Yield

0%

Description

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

Contact

SOUTH GLAMORGAN
Penarth
Avon HSE, 19 Stanwell Road
+447748960970.0
https://renalytix.com/

IPO

2018-11-06

Employees

-

Officers

CEO & Executive Director
Mr. James R. McCullough M.B.A.
President
Mr. Thomas H. McLain CPA, M.B.A
Chief Financial Officer
Mr. Oliver James Sterling III
CTO & Executive Director
Mr. Fergus Fleming
Chief Medical Officer
Dr. Michael J. Donovan M.D., Ph.D.
Chief Business Officer
Mr. Howard B. Doran Jr.
Show More
Company Secretary
Mr. Salim Gulamabbas Hamir F.C.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RENX stock?

The intrinsic value of one RENX stock under the Base Case scenario is 40.61 GBX.

Is RENX stock undervalued or overvalued?

Compared to the current market price of 33.5 GBX, Renalytix PLC is Undervalued by 18%.